drugset / Trial / NCT04778800
A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs. This study aims to explore the efficacy and safety of different doses of almonertinib in the first-line and second-line treatment of brain metastases/meningeal metastases in NSCLC patients.
Timeline
- Start
- 2021-03-20
- Primary completion
- 2023-02-20
- Completion
- 2024-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Almonertinib | Small molecule | 110 mg | Oral |
| Subject | Almonertinib | Small molecule | 160 mg | Oral |
| Subject | Almonertinib | Small molecule | 220 mg | Oral |